Yuhan is positioned as a smaller, innovative biopharma company with a single transformative asset, which contrasts sharply with global competitors like Pfizer, Merck, and AstraZeneca, which possess vast, diversified portfolios and multi-billion dollar R&D engines. High valuation and weak profits contrast with a strong balance sheet and high-potential drug, Leclaza.
Cyborg Score Rationale
Yuhan Corp stock analysis reveals a mixed outlook with high valuation and weak profits contrasting with a strong balance sheet and high-potential drug, Leclaza. Yuhan Corporation is overvalued, with current market price appearing to be based on optimistic future events, such as a major drug approval or a dramatic surge in profitability, rather than on existing financial health and performance.
Top Insights
Operating profit surged 190% amid revenue growth from anticancer drug Leclaza (2024-2025)
Trailing P/E ratio of 142.81x significantly exceeds pharmaceutical industry average of ~21x
Strong balance sheet provides buffer, but dividend yield of 0.43% offers minimal income support
Commercial execution of Leclaza against AstraZeneca's established Tagrisso blockbuster is paramount risk
Named Competitors
Leclaza — Innovative anticancer drug driving revenue growth
Tagrisso — Established blockbuster oncology competitor
Samsung Biologics — Top Korean biopharma competitor
Celltrion — Leading Korean biopharmaceutical company
Recent Developments
(January 2025) JPMorgan initiated coverage with Underweight rating
(July 2025) Made Later Stage VC investment in NOBO Medicine
(December 2025) Stock trading significantly below December 1 intrinsic value estimates
Open the full interactive Yuhan Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.